DOJ Gives Alibaba Non-Prosecution Deal, Downgrades Drug Safety Felonies
The Justice Department announced it will resolve its probe of Alibaba and its U.S. payment processor with non-prosecution agreements and misdemeanor charges instead of pursuing felony prosecutions.[1]
Under the agreements, Alibaba will pay a $125 million criminal penalty and forfeit $200 million, while AUS Merchant Services will pay an $85 million penalty and forfeit $190 million — about $600 million in total.[1]
In 2025 the Justice Department dissolved its Consumer Protection Branch and reassigned personnel to a Health & Safety Unit inside the Criminal Division's Fraud Section. Career prosecutors handling the Alibaba probe recommended a deferred prosecution that would have required Alibaba to admit felony violations of the Federal Food, Drug, and Cosmetic Act. DOJ leadership instead approved non-prosecution agreements that treated the conduct as misdemeanors. Federal agents made more than 40 undercover purchases and reviewed sales records from 2016 through 2024 during the investigation. A CBS video said Alibaba and its U.S. payment processor failed for roughly eight years to stop listings and sales of dangerous drugs, chemical precursors and pill presses that reached American consumers.[2] The segment said some Alibaba employees had warned internally about compliance problems during that period.[2]
CBS's July 9 evening segment emphasized evidence suggesting the company knowingly let dangerous drugs be sold and said the probe's findings were still being actively reported and scrutinized.[2] Career prosecutors criticized the decision to forgo felony charges as inadequate.
The mainstream summary does not address the significant evidence suggesting that Alibaba knowingly allowed dangerous drugs to be sold to U.S. consumers, as highlighted by career prosecutors at the DOJ. This oversight raises questions about the adequacy of the non-prosecution agreement, especially given that the investigation reportedly uncovered around 80,000 illegal pharmaceutical sales valued at over $200 million during an eight-year period. The decision to conclude with misdemeanors rather than felony charges appears to contradict the gravity of the findings, which included internal warnings from Alibaba employees about compliance issues. @SarahNLynch reports that this evidence was a critical factor in the prosecutors' push for felony charges, which were ultimately disregarded by DOJ leadership, suggesting a troubling trend in the handling of corporate accountability in such cases.
Additionally, the mainstream account fails to mention the broader context of declining strict criminal resolutions under the Federal Food, Drug, and Cosmetic Act (FDCA), which saw a drop to only four in 2025 from approximately 14 the previous year. This shift corresponds with a reorganization within the DOJ that has implications for how corporate misconduct is prosecuted, as noted by Gibson Dunn's 2025 update. Such changes may reflect a systemic issue in the enforcement landscape, where large corporations increasingly evade felony charges despite serious allegations. This context is crucial for understanding the implications of the DOJ's decision regarding Alibaba and its payment processor.[3][1]
Show source details & analysis (2 sources)
📊 Relevant Data
Alibaba agreed to pay a $125 million criminal monetary penalty and forfeit $200 million; AUS Merchant Services agreed to pay an $85 million criminal monetary penalty and forfeit $190 million under the non-prosecution agreements.
Alibaba Group and AUS Merchant Services Agree to Pay $600 Million to Resolve Allegations... — U.S. Department of Justice
Alibaba's quarterly revenue reached RMB 243.24 billion ($33.47 billion) in the three months ended June 30, 2024, with its China commerce retail businesses operating as the world's largest by GMV.
Alibaba Continues Solid Core Businesses Growth... — Alibaba Group
📌 Key Facts
- Over roughly eight years, Alibaba and its U.S. payment processor failed to prevent listings and sales that reached American consumers.
- The listings included dangerous drugs, chemicals and pill presses, according to the CBS video segment.
- Some Alibaba employees had internally warned about compliance problems during that period, per public records cited by CBS.
- CBS’s July 9, 2026 video segment reported the evidence suggesting the company knowingly let dangerous drugs be sold to U.S. consumers.
- The probe’s findings were still being actively reported and scrutinized as of Thursday, July 9, 2026, according to the CBS segment published that evening.
📰 Source Timeline (2)
Follow how coverage of this story developed over time
- CBS’s July 9, 2026 video segment emphasizes that for roughly eight years Alibaba and its U.S. payment processor failed to prevent dangerous drugs, chemicals and pill presses from being sold to American consumers.
- The segment highlights that some Alibaba employees had internally warned about compliance problems during that period, according to public records cited by CBS.
- Article publication timestamp shows the probe’s findings are still being actively reported and scrutinized as of Thursday, July 9, 2026.